Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M T Roe

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Current Cardiology Reports|September 12, 2000
Treatment strategies for microvascular dysfunction following acute myocardial infarctionM T Roe
The Journal of Emergency Medicine|May 25, 1999
Treatment of non-ST-segment-elevation acute coronary syndromes with platelet glycoprotein IIb/IIIa inhibitors: an emergency department perspectiveM T Roe, D J Moliterno
Poultry Science|April 25, 2003
Monitoring and identifying antibiotic resistance mechanisms in bacteriaM T Roe, S D Pillai
Thrombosis and Haemostasis|March 12, 2011
Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5)E M Ohman, M T Roe
Journal of Thrombosis and Thrombolysis|June 22, 1999
Emerging treatment of acute coronary syndromes with platelet glycoprotein IIB/IIIA inhibitorsM T Roe, D J Moliterno
Chest|October 1, 1996
Calcified cardiac lesionA K Gopal, M T Roe
Cleveland Clinic Journal of Medicine|May 26, 1998
The EPILOG trial. Abciximab prevents ischemic complications during angioplasty. Evaluation in PTCA to improve Long-Term Outcome with Abciximab GP IIb/IIIa BlockadeM T Roe, D J Moliterno
Cleveland Clinic Journal of Medicine|February 19, 2000
Glycoprotein IIb/IIIa inhibitors in acute coronary syndromesM T Roe, S K Sapp, A M Lincoff
The New England Journal of Medicine|December 5, 1998
Management of non-Q-wave myocardial infarctionM T Roe, T E Bowen, E J Topol
Cardiovascular Toxicology|September 6, 2002
Determination of the falloff constant (k(f)) from modeling biochemical marker release: a new variable for discriminating therapiesR H Christenson, S H Duh, M T Roe, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Current Cardiology Reports|September 12, 2000
Treatment strategies for microvascular dysfunction following acute myocardial infarctionM T Roe
The Journal of Emergency Medicine|May 25, 1999
Treatment of non-ST-segment-elevation acute coronary syndromes with platelet glycoprotein IIb/IIIa inhibitors: an emergency department perspectiveM T Roe, D J Moliterno
Poultry Science|April 25, 2003
Monitoring and identifying antibiotic resistance mechanisms in bacteriaM T Roe, S D Pillai
Thrombosis and Haemostasis|March 12, 2011
Explaining the unexpected: insights from the PLATelet inhibition and clinical Outcomes (PLATO) trial comparing ticagrelor and clopidogrel. Editorial on Serebruany "Viewpoint: Paradoxical excess mortality in the PLATO trial should be independently verified" (Thromb Haemost 2011; 105.5)E M Ohman, M T Roe
Journal of Thrombosis and Thrombolysis|June 22, 1999
Emerging treatment of acute coronary syndromes with platelet glycoprotein IIB/IIIA inhibitorsM T Roe, D J Moliterno
Chest|October 1, 1996
Calcified cardiac lesionA K Gopal, M T Roe
Cleveland Clinic Journal of Medicine|May 26, 1998
The EPILOG trial. Abciximab prevents ischemic complications during angioplasty. Evaluation in PTCA to improve Long-Term Outcome with Abciximab GP IIb/IIIa BlockadeM T Roe, D J Moliterno
Cleveland Clinic Journal of Medicine|February 19, 2000
Glycoprotein IIb/IIIa inhibitors in acute coronary syndromesM T Roe, S K Sapp, A M Lincoff
The New England Journal of Medicine|December 5, 1998
Management of non-Q-wave myocardial infarctionM T Roe, T E Bowen, E J Topol
Cardiovascular Toxicology|September 6, 2002
Determination of the falloff constant (k(f)) from modeling biochemical marker release: a new variable for discriminating therapiesR H Christenson, S H Duh, M T Roe, et al.
Pageof 3